Recent advancements in islet cell transplantation are offering new hope for individuals with type 1 diabetes (T1D). Supported by initiatives from the Juvenile Diabetes Research Foundation (JDRF), these breakthroughs aim to improve the effectiveness and accessibility of this promising treatment. For decades, T1D has required constant insulin management, but islet transplantation holds the potential to restore natural insulin production, freeing patients from daily injections and reducing long-term complications. With JDRF’s sustained investment in research, the field is witnessing transformative progress that moves beyond traditional limitations.

Understanding Islet Cell Transplantation

Islet cell transplantation involves isolating clusters of insulin-producing beta cells from a donor pancreas and infusing them into the liver of a person with type 1 diabetes. Once implanted, these islets begin to secrete insulin in response to blood glucose levels, mimicking natural pancreatic function. The procedure was first demonstrated successfully in the 1970s, but widespread adoption was hampered by low success rates. A major turning point came in 2000 with the Edmonton Protocol, which used a steroid-free immunosuppressive regimen and achieved insulin independence in a majority of recipients. However, the need for lifelong immunosuppression and limited donor supply remained significant barriers.

Challenges in Islet Cell Transplantation

Despite its potential, the procedure faces several persistent challenges that researchers continue to address:

  • Limited donor availability: Only a small fraction of the 1.6 million Americans living with T1D can receive a transplant due to the scarcity of deceased donor pancreata.
  • Immune rejection: Even with immunosuppressive drugs, transplanted islets can be attacked by the recipient's immune system, leading to graft loss over time.
  • Need for lifelong immunosuppressive drugs: These medications have serious side effects, including increased risk of infections, kidney damage, and certain cancers, limiting the procedure to patients with severe glycemic instability.
  • Islet survival and function: Many transplanted islets do not engraft or lose function due to inflammatory responses and inadequate blood supply in the liver.

Addressing these obstacles requires innovative approaches that JDRF has been actively funding through its research portfolio.

JDRF's Role and Initiatives

The Juvenile Diabetes Research Foundation (JDRF) is a global leader in T1D research, having invested over $2.5 billion since its founding. JDRF’s initiatives specifically target islet transplantation through dedicated programs like the Islet Transplantation Consortium, which facilitates multi-center clinical trials, and the Encapsulation and Hurdles in Cell Transplantation Research Network. These programs fund both academic and industry partners to accelerate translation from laboratory to clinic. JDRF also collaborates with the National Institutes of Health (NIH) and other foundations to leverage resources and reduce duplication. One notable initiative is the JDRF-funded Immunoengineering Initiative, which focuses on developing smart biomaterials and cellular therapies to protect transplanted cells without systemic immunosuppression. By providing early-stage funding and strategic guidance, JDRF has helped bring several breakthroughs from concept to clinical testing.

Recent Breakthroughs Supported by JDRF

JDRF initiatives have played a crucial role in overcoming the long-standing obstacles of donor scarcity, immune rejection, and immunosuppression. The following breakthroughs represent the most promising developments in recent years.

Encapsulation Technologies

Encapsulation protects transplanted islets from immune attack by surrounding them with a semi-permeable membrane that allows nutrients and insulin to pass but blocks immune cells and antibodies. This approach aims to eliminate the need for lifelong immunosuppressive drugs. Two main strategies are under investigation:

  • Macroencapsulation devices – Larger pouches or chambers that house hundreds of thousands of islets. The ViaCyte PEC-Encap device, partly funded by JDRF, demonstrated safety and viability in Phase 1/2 trials. A later version (PEC-Direct) allows vascularization but requires limited immunosuppression.
  • Microencapsulation – Individual islets are coated with alginate or other hydrogels, forming tiny beads that can be injected. Researchers at MIT and Harvard, with JDRF support, developed a modified alginate (TRI-7) that evades immune recognition in animal models and is now moving toward human trials.

Recent human trials of encapsulation devices have shown some islet survival for up to two years without immunosuppression, though insulin independence has not yet been achieved. JDRF continues to fund refinements to improve oxygen supply and durability of the encapsulation materials, with the goal of a durable, off-the-shelf product. A key clinical trial, NCT04678557, is evaluating an encapsulated porcine islet product in humans with JDRF support.

Stem Cell-Derived Islets

Perhaps the most transformative breakthrough is the ability to generate insulin-producing cells from human pluripotent stem cells. This approach addresses the critical donor shortage by providing an unlimited, standardized cell source. JDRF has been a primary funder of this research since its inception, including early work by Doug Melton at Harvard and later by companies like Vertex Pharmaceuticals and Semma Therapeutics (acquired by Vertex).

Vertex Pharmaceuticals’ VX-880 is a stem cell-derived, fully differentiated islet cell therapy. In early 2024, Vertex reported that the first patient treated with VX-880 achieved insulin independence and normal glucose levels (HbA1c below 6%) at 270 days post-transplant. Two additional patients showed similar dramatic improvements. The therapy requires immunosuppression, but Vertex is also developing an encapsulated version (VX-264) that may avoid this need. JDRF co-funded the initial discovery and later provided a $10 million grant to Vertex for scale-up manufacturing. This breakthrough was published in Nature and covered extensively in diabetes media.

Another approach involves using induced pluripotent stem cells (iPSCs) from the patient’s own cells, theoretically eliminating immune rejection. JDRF-supported researchers at the University of Florida and University of Chicago have developed protocols to generate islet-like clusters from iPSCs, though challenges with functional maturation and scalability remain. The Diabetes Research Institute (DRI) has also developed a BioHub platform that combines stem cell-derived islets with a biodegradable scaffold to improve engraftment, an approach funded by JDRF’s Encapsulation Consortium.

Immune Modulation

Rather than suppressing the entire immune system, new strategies aim to induce tolerance specifically to transplanted islets. JDRF has invested heavily in regulatory T cell (Treg) therapy and co-stimulation blockade. Tregs are a subset of lymphocytes that naturally suppress immune responses. By expanding a patient’s own Tregs and infusing them along with islets, researchers hope to create a local immune-privileged environment.

The Caladrius Biosciences trial (now part of XOMA) used Treg therapy combined with islet transplantation in a small Phase 2 study. Results showed that recipients required lower doses of immunosuppression and maintained graft function longer than historical controls. JDRF also supports the CTLA4-Ig (abatacept) and anti-CD40L antibodies as peri-transplant treatments; these molecules block co-stimulatory signals needed for T-cell activation. A landmark JDRF-funded trial by Markmann at Massachusetts General Hospital demonstrated that abatacept given during islet infusion reduced rejection episodes and allowed weaning of tacrolimus in some patients. These immune modulation strategies are now being combined with encapsulation and stem cell-derived islets in next-generation clinical protocols.

Clinical Impact and Patient Outcomes

The cumulative effect of these breakthroughs is beginning to reach patients. Clinical trial results from combined approaches show meaningful improvements in glycemic control and quality of life. The JDRF-funded Clinical Islet Transplant Consortium database reports that approximately 70% of recipients who receive two or more islet infusions achieve insulin independence for at least one year, and over 50% maintain partial graft function for five years. With newer immune modulation protocols, these rates are improving, and immunosuppression-related side effects are declining.

Patient case studies illustrate the impact: a 32-year-old woman with recurrent severe hypoglycemia who received stem cell-derived islets under JDRF’s VX-880 trial (Vertex) experienced stable glucose levels within two months and insulin independence at six months. She described the freedom from constant monitoring as “life-changing” in JDRF promotional materials. Another patient in the DRI’s BioHub trial with encapsulated islets reported a 75% reduction in severe hypoglycemic events, even without full insulin independence. Such outcomes are driving regulatory discussions; the FDA has granted breakthrough therapy designation to VX-880 and several encapsulation products.

However, durability remains a challenge. Many patients eventually require a return to small doses of insulin. JDRF is addressing this by funding long-term follow-up studies in its iTrans4 collaborative, which tracks over 200 transplanted patients for up to 10 years. Data from this registry inform adjustments to protocols and help identify factors that predict long-term graft survival.

Future Outlook and Ongoing Research

The next decade promises even greater advances as multiple JDRF-supported technologies converge. Key areas of ongoing research include:

  • Combination therapies: Encapsulated stem cell-derived islets combined with Treg infusion, eliminating the need for any systemic immunosuppression. Preclinical models show synergistic effects.
  • Improving islet function: Researchers are engineering islets with enhanced glucose sensing and insulin secretion through gene editing. JDRF’s Beta Cell Regeneration Program supports work to produce islets that are “super-functioning,” reducing the number needed for transplant.
  • Extrahepatic transplant sites: The liver is a hostile environment for islets. Alternative sites like the omentum, subcutaneous space, and peritoneum are being tested with specially designed scaffolds. JDRF-funded studies at the University of Miami show improved engraftment in the omental pouch using a fibrin-matrix.
  • Universal donor cells: Using gene editing (CRISPR) to create “universal” stem cells that evade immune detection by knocking out MHC molecules and expressing immune checkpoint proteins. JDRF has partnered with the CRISPR Therapeutics consortium on this front.
  • Scalable manufacturing: JDRF’s Cell Manufacturing Core helps fund processes to produce billions of stem cell-derived islets under Good Manufacturing Practice (GMP) conditions, essential for commercial viability.

JDRF also invests in health economics research to demonstrate cost-effectiveness, which will be critical for insurance coverage and regulatory approval. An analysis by the JDRF-funded Institute for Clinical and Economic Review (ICER) suggested that if an encapsulated stem cell product can maintain glycemic control for five years or more, it would be cost-effective compared to continuous insulin therapy.

Conclusion

JDRF initiatives have been instrumental in driving islet cell transplantation from a niche experimental procedure to a genuine therapeutic option. Through targeted funding of encapsulation, stem cell biology, and immune modulation, JDRF has accelerated the timeline toward a functional cure for type 1 diabetes. The breakthroughs of recent years — including insulin independence from stem cell-derived islets and immune-evasive encapsulation — represent milestones that bring us closer to a future where daily insulin injections are a memory. Ongoing collaboration between JDRF, academic institutions, pharmaceutical companies, and the diabetes community remains essential to overcome remaining hurdles such as long-term durability and cost. With continued support, islet cell transplantation could become a routine, accessible treatment within the next five to ten years, transforming the lives of millions worldwide.